International Stroke Conference 2022 (ISC 2022)
New Orleans, Louisiana, US 09 February 2022 - 11 February 2022
Tenecteplase still feasible up to 24 hours after a stroke
Intravenous thrombolysis with tenecteplase up to 24 hours after a stroke appears to re-establish blood flow in patients with large-vessel acute ischaemic stroke selected with advanced imaging, the phase IIa CHABLIS-T study has shown.
Tenecteplase still feasible up to 24 hours after a stroke
24 Feb 2022
Stroke risk elevated first 3 days post–COVID-19 diagnosis
Older patients with COVID-19 may have an increased risk of being hospitalized for acute ischaemic stroke (AIS), particularly in the first 3 days following their COVID-19 diagnosis, according to a study presented at ISC 2022.
Stroke risk elevated first 3 days post–COVID-19 diagnosis
18 Feb 2022
Tirofiban may improve outcomes in LAA strokes
While additional tirofiban prior to endovascular treatment (EVT) did not appear to benefit stroke patients with large vessel occlusion (LVO), it did seem to have an advantage for those with large artery atherosclerosis (LAA), findings from the RESCUE BT trial have shown.
Tirofiban may improve outcomes in LAA strokes
16 Feb 2022
The mouth a gateway to stroke risk reduction?
In individuals who had a recent stroke or transient ischaemic attack (TIA), a trip to the dentist might just spare them from a recurrence, findings from the PREMIERS* study suggest.